| 郝 瑞,梁 艳.口腔鳞状细胞癌患者血清cyfra21-1水平变化及其与患者临床病理特征及预后的相关性研究[J].肿瘤学杂志,2018,24(12):1176-1180. |
| 口腔鳞状细胞癌患者血清cyfra21-1水平变化及其与患者临床病理特征及预后的相关性研究 |
| Correlation Between Serum Cyfra21-1 Levels and Clinicopathological Features and Prognosis in Patients with Oral Squamous Cell Carcinoma |
| 投稿时间：2017-09-19 |
| DOI：10.11735/j.issn.1671-170X.2018.12.B007 |
|
 |
| 中文关键词: 口腔鳞状细胞癌 cyfra21-1 病理特征 预后 |
| 英文关键词:oral squamous cell carcinoma cyfra21-1 pathological features prognosis |
| 基金项目: |
|
| 摘要点击次数: 1573 |
| 全文下载次数: 515 |
| 中文摘要: |
| 摘 要：［目的］ 探讨口腔鳞状细胞癌（OSCC）患者血清cyfra21-1水平变化及其与患者临床病理特征及预后的相关性。［方法］ 选择接受手术切除的OSCC患者148例，术后病理确认 OSCC 68例（OSCC组，n=68），良性肿瘤80例（良性肿瘤组，n=80）。取癌旁的正常黏膜组织作为对照（对照组，n=68）。患者入院时，详细询问并记录其性别、年龄、吸烟史、嗜酒史、癌变部位、TNM分期、分化程度、淋巴结转移、局部浸润等临床数据。采用酶联免疫吸附测定法测定血清cyfra21-1水平，采用Kaplan-Meier法计算不同血清cyfra21-1水平患者累积生存率，运用Log-rank法进行比较。绘制受试者工作特征曲线（ROC）评估血清cyfra21-1水平预测OSCC患者预后效力。应用Cox比例风险回归分析影响OSCC患者预后的危险因素。［结果］ OSCC组患者血清cyfra21-1水平显著高于良性肿瘤组和对照组（P＜0.05），良性肿瘤组患者血清cyfra21-1水平与对照组比较差异无统计学意义（P＞0.05）。不同性别、年龄、癌变部位、吸烟史、嗜酒史患者间术前血清cyfra21-1水平比较差异无统计学意义（P＞0.05），不同TNM分期、分化程度、淋巴结转移、局部浸润患者间术前血清cyfra21-1水平比较差异有统计学意义（P＜0.05）。单因素、多因素Cox比例风险回归分析结果显示，Ⅲ~Ⅳ期、高分化、有淋巴结转移、血清cyfra21-1水平≥3.85 ng/ml不利于OSCC患者预后（P＜0.05）。血清cyfra21-1水平≥3.85ng/ml的OSCC患者5年累积生存率为64.15%，显著低于血清cyfra21-1水平＜3.85ng/ml的OSCC患者（P＜0.05）。［结论］ 术前血清cyfra21-1水平可作为预测OSCC患者预后的重要指标。 |
| 英文摘要: |
| Abstract：［Objective］ To investigate the changes of serum cyfra21-1 levels in patients with oral squamous cell carcinoma(OSCC) and their correlation with clinicopathological features and prognosis. ［Methods］ There was 148 cases with OSCC undergo surgical resection were selected as study subjects，OSCC of 68 cases were confirmed by pathological examination(OSCC group，n=68)，80 cases were benign tumor(benign tumor group，n=80). Normal mucosa tissues beside the cancer were taken as control(control group，n=68). Patients were asked for detailed records of their gender，age，smoking history，alcohol consumption history，location of cancer，TNM stage，differentiation，lymph node metastasis，local invasion and other clinical data. The level of serum cyfra21-1 was determined by enzyme-linked immunosorbent assay. The cumulative survival rate was calculated by Kaplan-Meier method in different serum cyfra21-1 levels，and then compared by Log-rank method. The receiver operating characteristic curve(ROC) was drawn to evaluate the serum cyfra21-1 level parameters and predict the prognosis of patients with OSCC. Cox proportional hazards regression analysis was used to analyze the risk factors of prognosis in patients with OSCC. ［Results］ The level of serum CYFRA21-1 in OSCC group was significantly higher than that in benign tumor group and normal control group(P<0.05)，and the serum cyfra21-1 level in the benign tumor group was not significantly different from that in the normal control group(P>0.05). There were no significant difference in preoperative serum cyfra21-1 levels between different gender，age，location of cancer，smoking history and alcohol consumption history(P>0.05)，there were significant differences in preoperative serum cyfra21-1 levels between patients with different TNM stages，differentiation，lymph node metastasis and local invasion(P<0.05). Single factor analysis and multi factor Cox regression showed that III~IV stage，high differentiation，lymph node metastasis，serum cyfra21-1 level≥3.85ng/ml were not conducive to the prognosis of patients with OSCC(P<0.05). The 5 year survival of the serum level of cyfra21-1≥3.85ng/ml OSCC patients was 64.15%，significantly lower than that of the serum level of cyfra21-1＜3.85ng/ml patients(P<0.05). ［Conclusion］ Preoperative serum cyfra21-1 levels can be used as an important predictor of prognosis in patients with OSCC. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |